Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1Endocrine 1Dermatologic 1CNS 1

Conditions

Vipoma 1Uveal Melanoma 1Somatostatinoma 1Small Cell Lung Carcinoma 1Pheochromocytoma 1Neoplasms 1Melanoma 1Lung Neoplasms 1Kidney Neoplasms 1Insulinoma 1Head and Neck Neoplasms 1Glucagonoma 1Gastrinoma 1Esthesioneuroblastoma, Olfactory 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Merkel Cell 1Carcinoma, Medullary 1Carcinoma, Islet Cell 1Adenoma, Islet Cell 1

Interventions

Trastuzumab 2veliparib 1tipifarnib 1pentetreotide 1Temozolomide 1Oxaliplatin 1Leucovorin 1Interleukin-12 Subunit p35 1Interleukin-12 1Floxuridine 1Capecitabine 190Y-octreotide, DOTA-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Vipoma × pentetreotide × Clear all
NCT00002947 2014-07-02

Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer

Yale University

Phase 1 Terminated
35 enrolled
CNSDermatologicEndocrineGenitourinaryHead & NeckThoracic

Uveal Melanoma, Carcinoma, Renal Cell, Vipoma, Glucagonoma, Head and Neck Neoplasms, Insulinoma, Adenoma, Islet Cell, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms, Pheochromocytoma, Somatostatinoma, Carcinoma, Merkel Cell, Gastrinoma, Central Nervous System Neoplasms, Carcinoma, Islet Cell, Carcinoma, Medullary, Esthesioneuroblastoma, Olfactory, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡